Buprenorphine implant - Titan Pharmaceuticals

Drug Profile

Buprenorphine implant - Titan Pharmaceuticals

Alternative Names: Buprenorphine implant; Probuphine

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Titan Pharmaceuticals
  • Developer Braeburn Pharmaceuticals; Knight Therapeutics; Titan Pharmaceuticals
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Opioid abuse
  • No development reported Pain

Most Recent Events

  • 09 Nov 2017 Titan receives notice of allowance for the buprenorphine implant in European Union
  • 06 Nov 2017 Preregistration for Opioid abuse in European Union (SC)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain in USA (SC, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top